Abilify and Primary sequestrum - a phase IV clinical study of FDA data

Summary:

Primary sequestrum is reported as a side effect among people who take Abilify (aripiprazole), especially for people who are female, 50-59 old, also take Megace, and have Arthritis.

The phase IV clinical study analyzes which people have Primary sequestrum when taking Abilify. It is created by eHealthMe based on reports of 97,308 people who have side effects when taking Abilify from the FDA, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,450 Abilify users. Check the latest studies of Abilify.

What is Primary sequestrum?

Primary sequestrum (piece of dead bone that has become separated during the process of necrosis from normal/sound bone) is found to be associated with 599 drugs and 327 conditions by eHealthMe. Check the latest studies of Primary sequestrum.

On Apr, 17, 2026

97,308 people reported to have side effects when taking Abilify.
Among them, 8 people (0.01%) have Primary sequestrum.

Among these 8 people:

What is the gender of people who have Primary sequestrum when taking Abilify? *

female: 87.5 %
male: 12.5 %

What is the age of people who have Primary sequestrum when taking Abilify? *

What are other drugs people take besides Abilify? *

What are other side effects people have besides Primary sequestrum? *

Cardiomyopathy (weakening of the heart muscle): 8 people, 100.00%
Lymphadenopathy Mediastinal (an enlargement of the lymph nodes in the part of the chest that separates the lungs): 8 people, 100.00%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 8 people, 100.00%
Neuropathy Peripheral (surface nerve damage): 8 people, 100.00%
Nerve Injury: 8 people, 100.00%
Cluster Headache (one-sided head pain with tearing): 8 people, 100.00%
Consciousness - Decreased: 8 people, 100.00%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 8 people, 100.00%
Dental Caries: 8 people, 100.00%
Dental Plaque (film of mucus and bacteria deposited on the teeth that encourages the development of dental caries): 8 people, 100.00%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 8 people, 100.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 8 people, 100.00%
Breast Cancer Recurrent: 1 person, 12.50%
Aspergillosis (an infection caused by a fungus called aspergillus): 1 person, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and have Primary sequestrum?

- Check whether Primary sequestrum is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abilify:

Abilify (101,450 reports)

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Primary sequestrum:

Primary sequestrum (599 drugs)

Browse all the conditions that are associated with Primary sequestrum:

Primary sequestrum (327 conditions)

Related publications that referenced our studies

Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .
Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole (the active ingredients of Abilify) and Abilify (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.